Novozymes A/S (NASDAQ:NVZMY) Stock Rating Upgraded by Zacks Investment Research

Novozymes A/S (OTCMKTS:NVZMY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Friday, October 27th. The firm currently has a $61.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 12.26% from the company’s previous close.

According to Zacks, “Novozymes A/S is primarily engaged in the development, production, and distribution of enzymes. Its business consists of two segments, enzyme business and bio business. The Company’s enzyme business segment offers detergent enzymes that are used in laundry and dishwashing, technical enzymes used in the transformation of starch into different kinds of sugars and have application in leather, textile, and forest product industries, food enzymes used in production of bread, wine, juice, beer, noodles, alcohol, and pasta and feed enzymes used in animal feed. Its bio business segment offers microorganisms that are used in industrial and municipal wastewater treatment, as well as in the cleaning of surfaces such as carpet, concrete, drain lines, and septic tanks in industrial and household applications. It also has application in the Biopharmaceutical ingredients used in pharmaceutical industry. Novozymes A/S is headquartered in Bagsvaerd, Denmark. “

Separately, Jefferies Group LLC reaffirmed a “hold” rating and set a $54.97 price objective on shares of Novozymes A/S in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Novozymes A/S has a consensus rating of “Hold” and an average price target of $57.99.

Novozymes A/S (OTCMKTS:NVZMY) opened at $54.34 on Friday. Novozymes A/S has a 1 year low of $31.57 and a 1 year high of $56.06. The company has a market capitalization of $13,653.27, a P/E ratio of 34.83, a price-to-earnings-growth ratio of 2.57 and a beta of 1.11.

Novozymes A/S (OTCMKTS:NVZMY) last released its quarterly earnings data on Friday, August 11th. The biotechnology company reported $0.36 EPS for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). Novozymes A/S had a net margin of 21.52% and a return on equity of 28.52%. The company had revenue of $522.72 million during the quarter. equities analysts predict that Novozymes A/S will post 1.69 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/11/13/novozymes-as-nvzmy-upgraded-to-buy-by-zacks-investment-research.html.

About Novozymes A/S

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America.

Get a free copy of the Zacks research report on Novozymes A/S (NVZMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply